RT Journal Article
SR Electronic
T1 Tranilast Inhibits TRPV2 and Suppresses Fibrosis Progression and Weight Gain in a NASH Model Mouse
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3593
OP 3604
DO 10.21873/anticanres.17182
VO 44
IS 8
A1 NAGATA, TAKAHIRO
A1 SHAKADO, SATOSHI
A1 YAMAUCHI, ERI
A1 TOKUSHIGE, HIROAKI
A1 MIYAYAMA, TAKASHI
A1 YAMAUCHI, RYO
A1 FUKUDA, HIROMI
A1 FUKUNAGA, ATSUSHI
A1 TANAKA, TAKASHI
A1 TAKATA, KAZUHIDE
A1 YOKOYAMA, KEIJI
A1 HIRAI, FUMIHITO
YR 2024
UL http://ar.iiarjournals.org/content/44/8/3593.abstract
AB Background/Aim: This study aimed to investigate the role of transient receptor potential vanilloid 2 (TRPV2) in a mouse model with non-alcoholic steatohepatitis (NASH) and to examine the effects of tranilast on TRPV2 and fibrosis-related cytokines. Materials and Methods: C57BL/6N mice were fed a Gubra-Amylin NASH (GAN) diet for 20 weeks to induce NASH. The tranilast groups received oral administration of tranilast at doses of 300, 400 and 500 mg/kg/day, five days per week for 20 weeks, in addition to the GAN diet. The effects of tranilast were assessed based on the dosage of food intake, changes in body weight, liver weight, blood biochemical parameters, histopathological examination, and expression of TRPV2 and inflammatory cytokines. Results: Hepatic expression of TRPV2 was observed in the GAN-fed NASH mouse model. The tranilast groups showed significantly suppressed increases in body and liver weights. The development of intrahepatic fat deposition and liver fibrosis, assessed histopathologically, was inhibited. Tranilast administration improved the expression of TRPV2 and inflammatory cytokines in the liver. Additionally, blood tests indicated a reduction in elevated liver enzyme levels. Conclusion: In GAN diet NASH models, TRPV2 was up-regulated in the liver and tranilast inhibited TRPV2 and suppressed fibrosis. Therefore, it might prevent the incidence of hepatocellular carcinoma associated with NASH.